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Summary 
Background & aims: Delayed gastric emptying (DGE) commonly limits the use of enteral nutrition 
(EN) and may increase ventilator-associated pneumonia. Nasointestinal feeding has not been tested 
against dual prokinetic treatment (Metoclopramide and Erythromycin) in DGE refractory to 
metoclopramide. This trial tests the feasibility of recruiting this ‘treatment-failed’ population and the 
proof of concept that nasointestinal (NI) feeding can increase the amount of feed tolerated (% goal) 
when compared to nasogastric (NG) feeding plus metoclopramide and erythromycin treatment. 
 
Methods: Eligible patients were those who were mechanically ventilated and over 20 years old, 
with delayed gastric emptying (DGE), defined as a gastric residual volume ≥250 ml or vomiting, and 
who failed to respond to first-line prokinetic treatment of 3 doses of 10 mg IV metoclopramide over 
24 h. 
When assent was obtained, patients were randomised to receive immediate nasointestinal tube 
placement and feeding or nasogastric feeding plus metoclopramide and erythromycin (prokinetic) 
treatment. 
 Results: Of 208 patients with DGE, 77 were eligible, 2 refused assent, 25 had contraindications to 
intervention, almost exclusively prokinetic treatment, and it was feasible to recruit 50. Compared to 
patients receiving prokinetics (n=25) those randomised to nasointestinal feeding (n=25) tolerated 
more of their feed goal over 5days (87 – 95% vs 50 – 89%)and had a greater area under the curve 
(median[IQR] 432 [253 – 464]% vs 350 [213  – 381]%, p = 0.026) demonstrating proof of concept. 
However, nasointestinally fed patients also had a larger gastric loss (not feed) associated with the NI 
route but not with the fluid volume or energy delivered. 
 
Conclusions: This is first study showing that in DGE refractory to metoclopramide NI feeding can 
increase the feed goal tolerated when compared to dual prokinetic treatment. Future studies should 
investigate the effect on clinical outcomes. 
 
Glossary 
CRRT  continuous renal replacement therapy 
DGE  delayed gastric emptying 
EN  enteral nutrition 
GRV  gastric residual volumes 
NG  nasogastric 
NI  nasointestinal 
PN  parenteral nutrition 
SAE  serious adverse events 
SAR  serious adverse reactions 
TPN  total parenteral nutrition 
VAP  ventilator-associated pneumonia 
 
Take home message 
Under-nutrition in ICU is associated with poor outcome and commonly caused by delayed gastric 
emptying (DGE). In patients with DGE refractory to metoclopramide treatment, a higher percentage 
of goal nutrition is tolerated via intestinal feeding than gastric feeding plus dual metoclopramide and 
erythromycin treatment. 
 
Tweet 
Goal nutrition is better tolerated via intestinal feeding than with gastric feeding plus dual 
metoclopramide and erythromycin treatment 
1. Introduction 
 
Attempting to meet goal requirements using enteral nutrition (EN) may be associated with 
reductions in mortality, infection, hospital stay and nutritional deficit [1]. However, delayed gastric 
emptying (DGE) limits the use of EN and may be associated with increased risk of ventilator-
associated pneumonia (VAP) [2]. NI feeding and total parenteral nutrition (TPN) can overcome DGE 
and may reduce VAP-risk but nasointestinal (NI) EN is cheaper and reduces infection risk [1] by 
maintaining gut immunocompetence [3].  
 
Delayed gastric emptying (DGE) presents in 30.5% of ICU patients [4]. DGE is associated with 
increased mortality and time to discharge alive, lower energy and protein input and fewer ventilator-
free days after adjustment for age, sex and APACHE score, particularly when it persists >1d or 
relapses [4]. Cumulative 24 h gastric residual volumes (GRVs) of even 150 mL are associated with 
objectively measured DGE [5]. However, while DGE is associated with increased retrograde intestinal 
peristalsis [6] prokinetic drugs such as metoclopramide and erythromycin improve gastric emptying 
and reduce intolerance due to large GRVs and vomiting [7]. And, the improved intestinal nutrient 
delivery following erythromycin increases glucose absorption [8] and is tolerated without ileus in 
most patients on full rate NI feeding [9].  
 
Evidence on whether prokinetics or NI feeding are more effective in over-coming DGE is equivocal. 
When NI feeding is delayed, nasogastric (NG) feeding delivers more EN during erythromycin 
treatment [10] and achieved similar EN delivery and clinical outcomes during metoclopramide and 
erythromycin treatment [11]. Conversely, rapid NI tube placement was associated with greater 
tolerance (%goal), a smaller cumulative deficit and reduced prokinetic drug use and treatment cost 
[9]. 
 
Treatments are not risk-free. It has been recommended that gastric feeding is not interrupted when 
the GRV is less than 500 ml but that prokinetic drugs are initiated when GRVs are 200 – 500 ml [12]. 
However, prokinetic use is associated with early tachyphylaxis (metoclopramide: 2 – 3 days; 
metoclopramide + erythromycin: 6 days) [13] and side-effects (metoclopramide: neurological [14], 
erythromycin: cardiac and potential bacterial resistance). Conversely, additional ‘blind’ NI tube 
placement adds a 1.5% risk of misplacing the tube in the respiratory tract and 0.5% risk of 
pneumothorax or pneumonia [15]. 
 
This is the first trial to test the feasibility of recruiting patients with proven DGE where first-line 
prokinetic (metoclopramide) treatment has failed. We study the proof-of-concept of whether NI 
feeding immediately post-randomisation increases the feed goal (%) tolerated compared to NG 
feeding plus metoclopramide and erythromycin prokinetic treatment. Earlier studies recruited 
patients ‘at risk’ of DGE and only confirmed intestinal feeding 15 h after tube placement [11]. 
2. Methods 
 
This was a randomised, feasibility and proof-of-concept study. Ethical (NRES Committee South 
Central –  Southampton A, REC reference: 12/SC/0530) and Medicines and Healthcare products 
Regulatory Agency (MHRA) (18524/0221/001-0001) approval was obtained prior to commencement. 
Intervention blinding was not possible because the research team placed the enteral tubes whilst 
sham tubes are both discernible and an inherent complication risk. 
 
The study was undertaken at Frenchay Hospital ICU admitting approximately 600 patients per year, 
66% non-surgical, a mean APACHE II score of 16 ± 7.2 and overall predicted mortality of 33%. 
Mechanically ventilated adults receiving EN were eligible at any point post-ICU admission if they had 
DGE (vomiting or 1 GRV exceeded 250 mL) after first-line prokinetic treatment of three 10 mg doses 
of IV metoclopramide over 24 h [9]. Based on scintigraphy in critically patients, a GRV of 250 mL in 
24 h approximates the lowest threshold at which only patients with DGE will be captured and 
therefore permits earlier treatment of DGE compared to higher thresholds [5]. Mechanical 
ventilation was defined as presence of an endotracheal tube or tracheostomy excluding those on 
CPAP alone or breathing spontaneously. Patients were excluded if prokinetics were contraindicated 
(erythromycin: 
on macrolides, metoclopramide: <20y) [1], EN had become contraindicated because the GI tract was 
not accessible or functional including ileus, active GI bleeding, intestinal obstruction and potential GI 
ischaemia, EN was considered ineffective when moribund or anticipated EN requirement was for <48 
h, if the EN goal was unattainable including those with severe malnutrition, short bowel syndrome, 
substrate intolerance, renal failure (serum creatinine >190uM) and not on continuous renal 
replacement therapy and hepatic encephalopathy necessitating protein restriction, or where an NI 
tube was contraindicated due to abnormal anatomy or surgery or was already in situ. 
 
2.1. Recruitment and randomisation 
 
Assent was obtained from relatives or a non-research ICU consultant for study admission until 
informed patient consent was possible. Researchers numbered each recruit then email requested 
allocation via an automated, concealed, random block, 1:1 ratio randomiser. 
 
2.2. Feeding and gastrointestinal (GI) intolerance 
 
All patients were increased from 40 mL feed/h or current rate to full rate whenever tolerated. 
Tolerance was defined GRVs <250 mL and no vomiting in the prokinetic group and where GRVs 
contained no macroscopic feed in the NI group. The first GRV ≥250 mL was discarded and EN was 
continued at the same rate but a second consecutive 4 hourly GRV ≥250 mL was discarded and the 
feed rate was reduced 50%. Ileus triggered cessation of EN and 4 hourly re-assessment for risk of 
bowel ischaemia [16]. 
 
2.3. Outcome, treatments and study size 
 
Primary outcome was the percentage of feed goal tolerated (% goal). The research dietitian 
prescribed the ‘goal’ feed type and volume, based on individualised estimation of energy 
expenditure from validated ‘PSUm’ equations, less non-nutritional energy from IV glucose or the fat 
solvent in Propofol and ≥1.2 g protein/kg/ d [17].When substrate intolerance was a risk (BMI >30, 
diabetes) or present (serum glucose >10 mM), ‘goal’ was reduced from 100% to 75% of energy 
expenditure. The volume of feed tolerated was a pragmatic estimate: NI feed + (NG feed * (total NG 
fluid - discard)/total NG fluid). When NI feed was clinically visible in a GRV or vomit it was counted as 
NG feed.  
 
When eligible patients failed to respond to 3 doses of metoclopramide over 24 h and assent was 
obtained, they were randomised either to receive 250 mg IV erythromycin qds in addition to 
metoclopramide [18] or NI feeding (Fig. 1). The NI tube guide-wire emits an electromagnetic signal, 
detected by a ‘receiver’ over the xiphisternum and projected as a computerised trace of the tube 
path to guide placement [14]. If NI placement failed, the patient received both prokinetic drugs but 
where it succeeded both drugs were stopped. All patients had an NG tube left in situ to check 4 
hourly GRVs and NG feed ‘prokinetic’ patients or freely drain in ‘NI’ patients. 
 
Historically, 21% of Frenchay ICU patients met our inclusion criteria, giving 129 potentially eligible 
patients per year; reduced by potential refusal (<20% [19]) and weekends and within grant 
constraints, 
we aimed to recruit 50 patients per group. We tested the feasibility in recruiting DGE patients failing 
first-line prokinetic treatment and hope to prove the concept that immediate NI feeding would 
reduce the goal deficit over 5 days [9].  
 
2.4. Clinical outcomes 
 
As a foundation for studying the effect of treating DGE on VAP risk, we report clinical outcomes 
during the 5-day study period. Adverse events or reactions included: Diarrhoea (≥3 liquid stools per 
day), abdominal distension (clinically compared to baseline), vomit or regurgitation, minor nose-
bleed, continuous renal replacement therapy (CRRT, in patients in stage 3 – 4 renal failure pre-
randomisation) and hypernatraemia. Serious adverse events (SAEs) or reactions (SARs) included: 
Systemic infection (SIRS: Any two of temperature >38.3 or <36 °C, respiratory rate >20 min-1 or 
PaCO2 <32 mmHg (4.3 kPa), heart rate >90 bpm, total white cell count <4 × 109/L or >12 ×109/L or 
sepsis: SIRS + presence of an infection) [20,21], ileus (identification of abdominal distention and lack 
of bowel movement, having excluded GI obstruction on clinical or radiological grounds), raised liver 
function tests (>3 × upper limit for bilirubin, alanine transaminase or alkaline phosphatase). 
 
2.5. Statistical analysis 
 
Statisticians performed ‘blind to intervention’, intention-to-treat analyses. Normality of continuous 
variables was determined by a Shapiro-Wilks test (p<0.05) and an independent samples Student's t 
test or Mann-Whitney test as appropriate. The 95% confidence intervals (95%CI) refer to the mean 
or median difference between treatment groups in the respective tests. Categorical data was 
analysed using Fisher's exact test. Results will be used to guide sample size for future full trial. 
Associations were tested using linear regression. Effect sizes ([mean of intervention e control]/ 
standard deviation) and bootstrapped 95%CI for medians were calculated and presented with the 
percentage difference between intervention and control. Analyses for continuous and categorical 
variables were done using Cohen's d and Cramer's V tests, respectively. A Mann-Whitney test was 
used to determine the difference of the area under the curves of feed goal (%), to provide an overall 
p-value over the 5 days of the intervention or up to the point of death. 
 
3. Results 
 
The study ran from22/2/13 to 12/5/14 including 5 days follow-up. Of 25 patients randomised to 
receive NI feeding, 92% had an NI tube placed on day 1, usually within 1 h of randomisation by the 
ICU dietitian (ST). Metoclopramide was continued in three ‘NI’ patients because the patient was in 
theatre or the tube failed to move out of the stomach or duodenum part-1. All three tubes were 
advanced into the intestine on day-2 and metoclopramide was stopped: 100% of tubes were 
intestinal, 92% in duodenum part-4 or beyond. Surviving NI patients inadvertently removed tubes in 
8% by day-3 and 16% by days 4 – 5. Prokinetics were started within 3 h of randomisation in 24 of 25 
patients randomised. However, patient 5 was re-classified ‘moribund’ before treatment on day-1, 
patient 32 failed to respond to prokinetic treatment and was successfully transferred to NI feeding 
from day 5 and patient 50 suffered a suspected serious adverse drug reaction to erythromycin and 
treatment was stopped on day 3. However, results were analysed on an intention-to-treat basis. 
 
A quarter of ICU patients with DGE were refractory to metoclopramide and recruited (Fig. 1). In 27% 
DGE resolved with metoclopramide treatment whereas ~12% may have required treatment but 
were excluded because they were not mechanically ventilated. There was no apparent association 
between APACHE II score or age and failure to respond to metoclopramide. About 5% were excluded 
because of protocol deviation due to early treatment cessation of metoclopramide or initiation of 
erythromycin. Only 1% refused assent. Most of the remainder had absolute, if temporary, reasons 
for 
not being treated. However, patients with DGE were twice as likely (11.3% vs 4.9%) to be excluded 
from prokinetic drug treatment (potential metoclopramide sensitivity or erythromycin drug 
interactions) as NI tube placement. Randomisation was restricted by weekends and leave of the 
single operator for NI placement. If operators provided full clinical cover, more patients suffering 
DGE are 
eligible for NI feeding than dual metoclopramide and erythromycin treatment (99.5% vs 88.7%, p < 
0.0001; Cramer's V = 0.25). 
 
Age and APACHE II score were similar for ‘inclusions’ and ‘exclusions’ but exclusions had significantly 
more ICU and ventilator free days up to day 28 and a non-significant trend to increased mortality 
(Appendix A). Study groups were similar for all baseline measures (Table 1). 
 
The NI intervention exceeded feed goal tolerance of prokinetics on 68 – 76% of patient days (Fig. 2). 
On days 4 and 5 the disparity is mainly because tolerance fell in the ‘prokinetic’ group. Days 1– 5, the 
area under the curve of feed goal (%) for the NI group was higher (median [IQR] 432 [253 – 464]% vs 
350 [213 – 381]%, p = 0.026) demonstrating proof of concept and >80% was tolerated on 16 – 40% 
patient days more than the ‘prokinetic’ group. While the NI group received a higher enteral volume 
via EN and a trend to higher kcal delivered, 5 – 42% of NI patients had a higher gastric loss (not feed) 
than the NG group's median, particularly on days 1e3 (Appendix B). In a linear model, higher gastric 
loss was associated with the ‘NI’ intervention, but not EN volume or kcal delivered. Furthermore, 
regression analysis of age, APACHE II score, disease category, conscious state, airway, height, weight 
and study group, showed only NI feeding and ‘surgery’ diagnosis had significant independent 
associations with lower and higher cumulative deficits, respectively (Appendix C). 
 
Groups were similar for minor and major complications and mortality (Table 2). Numbers were too 
small for analysis but the NI group had fewer infectious complications and days on PN but more 
cases of ileus diagnosed (Appendix D). Treatment groups had a similar number of minor 
complications associated with the intervention (NI feeding: 2 minor nose bleeds, Prokinetics: 
Erythromycin stopped because of ileus [n = 1] and skin rash [n = 1]). However, prokinetic drugs were 
stopped in two patients from that group: 1 because treatment failed to correct DGE by day 4 and 1 
because of severe tachycardia, ectopics and loss of cardiac output suspected to be a serious adverse 
drug (erythromycin) reaction. 
 
4. Discussion 
 
4.1. Primary outcome 
 
For the first time we demonstrate that 24% of patients with DGE fail first-line prokinetic treatment, 
can be recruited and prove the concept that NI feeding achieves higher goal (%) feed tolerance days 
1e5 than dual prokinetic treatment (p = 0.026).Median tolerance was greater in NI than prokinetic 
patients on 68 – 76% patient days. There were minimal differences between groups at baseline or 
for clinical outcomes, though the study was not powered to determine the latter. 
 
Relatively greater tolerance in the ‘NI’ group on day 1 may be due prokinetic effects being slower 
than instant intestinal access whereas on days 4e5 feed tolerance is maintained in the NI group but 
fell in the prokinetic group. Previous studies showed that the number of patients being successfully 
fed when receiving metoclopramide drops from 62% to 27% and 16% after 24 h, 3 and 7 days, 
respectively 
[13]. Similarly, successful feeding on erythromycin treatment falls from 87% to 47% and 31% at 24 h, 
days 3 and 7, respectively. Combined treatment using both drugs was effective in 67% up to day 6. 
We confirm that tolerance using combined metoclopramide-erythromycin treatment peaks at 88% 
on day 3 but falls to between 60 and 72% days 4 – 5. This suggests early tachyphylaxis, rather than 
our policy of stopping prokinetics after 48 h of improved tolerance, as prokinetic doses were not 
associated with tolerance. In contrast, NI group tolerance was 88% on day 1 and plateaued at 95%. 
Since 16% of NI tubes were lost to patient removal, use of nasal bridles might further improve 
success. Increasing the number of patients receiving >80% of goal nutrition by 7 – 18% was 
previously associated with shorter mean stay in hospital (25 vs 35 days) and a trend toward reduced 
mortality (27% vs 37%) [22]. Since our study increased the number of patients reaching this goal by 
16 – 40% over days 1 – 5, the intervention may benefit clinical outcomes.  
 
Our estimation of feed tolerance from NI feed þ (NG feed * (total NG fluid  – loss)/total NG fluid) is 
an approximation because currently there are no accurate clinical methods for measuring gastric 
emptying. Because we classified ‘NI’ feed seen in a GRV as  ‘NG’ on the assumption that either the 
tube or feed had regurgitated into the stomach, NI feeding may have been underestimated since 
only a proportion of intestinal feed is likely to have been regurgitated. Conversely, NG feed and fluid 
may be diluted by saliva and gastric juice, therefore feed loss in GRVs may be overestimated. 
Refractometry is an inexpensive measure of gastric emptying [23] but dilution leads to 
overestimation of gastric emptying and repeated sampling is difficult to apply in clinical settings. It is 
also possible that our definition of ‘tolerance’ does not equate to absorption and its possible benefit. 
Intestinal glucose absorption and glucose-transporters are reduced in critical illness [24]. Conversely, 
glucose absorption increases following erythromycin [8] and few patients suffer ileus during NI 
feeding [9]. It has not been determined whether or to what extent malabsorption or harm occur or 
are reversed by continuous intestinal nutrient delivery.  
 
4.2. NI tube success 
 
NI feeding previously failed to improve goal (%) tolerated [11,25]. Our study differed in having early 
and high NI tube placement success (1 h: 92%, 24 h: 100%) and feeding, equal to the best alternative 
techniques [26]. Tubes relying on peristalsis, have lower success rates (60e90%) and greater delays 
before placement confirmation (1.5 – 5 days) [11,27]. Fluoroscopy may achieve 96 – 100% success 
rates [28] but is rarely available at the bedside. 
 
4.3. Gastric loss 
 
Interestingly, while NI feeding by-passes DGE and reduces GRVs in some individuals, overall, we 
confirm that NI feeding is associated with higher gastric losses [9]. NI feeding may accentuate an 
underlying mechanism for DGE, the hypersensitive secretion of cholecystokinin (CCK) and peptide-YY 
(PYY) [29], in response to nutrient entering the small intestine, leading to reduced antral and fundal 
tone but increased pyloric tone [30]. Tending to confirm this, gastric loss was associated with site of 
delivery (NI intervention group) but not enteral volume or energy (kcal) delivered. If NI feeding alone 
increased DGE and aspiration risk relative to prokinetics, it helps explain failure to improve clinical 
outcomes [11]. However, while pepsin-positive tracheal secretions occur in 62% of NG-fed ventilated 
patients [31] our combination of NG drainage concurrent to NI feeding should additively reduce 
aspiration risk [2]. 
 
4.4. Safety and clinical outcomes 
 
There were only 2 minor treatment-related complications in each group. However, prokinetics were 
stopped in two patients: one after a serious suspected erythromycin-related cardiac complication 
and one because there was no improvement in DGE by day 4. The small numbers preclude 
conclusions regarding the NI vs prokinetic difference in ileus (3 vs 2) and systemic infection (2 vs 5). 
Regarding ileus, mechanical ventilation in sedated patients with traumatic intracranial haemorrhage 
is not only associated with DGE but also prolonged small bowel and overall transit time [32]. Our 
results suggest that overcoming the DGE component facilitates adequate EN tolerance in the 
majority, while lower GI dysfunction may temporarily preclude this with ileus in ~12%; this needs to 
be confirmed in a larger study.  
 
Limitations of this study include inability to perform ‘intervention blinding’ or quantify gastric 
emptying, introducing potential bias and reducing the efficacy in recruiting the target group, 
respectively. However, the concealed, mixed block randomisation method would reduce risk of 
allocation bias and the effect size for NI feeding improving EN tolerance, in patients with a wide 
range of primary conditions, was above a level that was previously shown to significantly improve 
clinical outcome [22].  
 
4.5. Future 
 
Meta-analysis indicates that compared to NG feeding, NI feeding reduces risk of pneumonia and 
VAP, even when limiting to studies using microbiological data, and increases nutrient intake [33– 
35]. 
Other clinical outcomes were similar, possibly because of rapid response to antibiotics in early 
pneumonia. In addition, many studies failed to report success of NI tube placement or delays to 
feeding. These factors and inclusion of patients without proven DGE would limit any advantage from 
NI feeding. Indeed the largest multi-centre study recruited patients at risk of DGE within 72 h of ICU 
admission, when DGE may not have existed or was most likely to self-resolve and when factors other 
than DGE are likely to affect EN delivery, including their slower method of achieving and confirming 
NI tube placement. Lastly, patients intolerant to EN after 48 h of prokinetic treatment were allowed 
to crossover to NI feeding. Clinical outcomes could be different when restricting inclusion to patients 
with proven DGE and starting NI feeding within 1– 2 h of randomisation. 
 
We propose that an adequately powered study is required to determine the efficacy of NG feeding 
plus prokinetics vs NI feeding in preventing VAP where eligibility is restricted to patients with DGE at 
highest risk of aspiration (GRVs of ≥250 mL or vomiting) [36] and poor outcomes (refractory to 
prokinetic treatment) [4]. Although complications were not increased by omitting GRV checks [37], 
this may not apply to high risk patients (surgical, shock) [38] or permit timely treatment to shorten 
intolerance [4]. In addition, in a larger, multicentre study, tolerance might be analysed using a 
repeated measures approach to determine an optimal time to stop an intervention. A precursor 
study would need to provide proof that new centres can be trained to achieve similar speed and 
success in placement of NI tubes.  
 
While prokinetic treatment is initially effective in treating DGE, its effect declines after day 3 and 
safety issues precluded prokinetic use in more patients than NI feeding (11.3% vs 0.5%). However, 
compared to NG feeding, greatest risk reduction for aspiration and pneumonia is when NI feeding is 
deeper than duodenum part-3 [2]. Conversely, blind tube placement resulting in proximal duodenal 
feeding [39] and increased duodeno-gastric reflux [40] or increased VAP-risk from transporting a 
patient off ICU for fluoroscopic placement [41] are reasons for failure to improve outcome; bedside 
jejunal placement accompanied by gastric drainage appear preferable [2]. Lastly, bed-rest elevation 
must be controlled because aspiration risk falls by -3.8% per 10° [2].  
 
Defining VAP diagnosis will be important. The clinical pulmonary infection score (CPIS) misclassifies 
about half of patients (sensitivity 50%, specificity 58%) but diagnostic accuracy is increased with 
addition of Gram staining (85% and 49%), blind protected sampling (78% and 56%) [42] or diagnosis 
from protected bronchial lavage. 
 
5. Conclusion 
 
Combined metoclopramide and erythromycin treatment during NG feeding or NI feeding are 
effective means of increasing goal (%) feed tolerance and widely applicable to patients suffering 
DGE. However, guided NI tube placement achieves high success rates and NI feeding more quickly 
and better maintains feed tolerance (% goal). Future studies should consider including only patients 
suffering DGE, use rapid bedside NI tube placement and simultaneous NG drainage. 
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Fig. 1. Enrolment, allocation, follow-up and analysis 
 N NG + 
prokinetics 25 25 25 24 24 23 23 
NI 24 24 25 24 23 23 22 
Effect Size 0.02 0.21 0.4 0.19 0.19 0.18 0.17 
 95% CI -22, 23 0, 23 -44, 4 -19, 4 -17, 4 -47, 5 -25, 4 
% of NI > median NG 60 40 76 68 72 72 76 
 
Fig. 2. Median goal (%) tolerated 
  
Table 1 Baseline characteristics of prokinetic vs NI groups. 
Parameter NG + prokinetics  NI Effect:  
 Median IQR Median IQR Size 95%CI % of NI  
> median NG 
Age (y) 51 36-59 53 42-61 0.09 0.21, 0.36 56% 
APACHE II score 20 13-19 18 12-24 0.03 -0.24, 0.31 40% 
Height_measured (cm) 178 166-180 173 171-180 0.04 -0.27, 0.33 40% 
Weight_estimate (kg) 80 73-110 75 70-85 0.15 -0.13, 0.42 36% 
        
Parameter N % N %    
Sex (m) 18 72% 20 80% 0.09 0, 0.36 - 
C 
A 
T 
E 
G 
O 
R 
Y 
■ Medical 7 28% 9 36% 0.14 0.08, 0.48 - 
■ Neurosurgery (non-
trauma) 
9 36% 6 24% 
■ Surgery (abdominal)) 3 12% 4 16% 
■ Trauma 6 24% 6 24% 
 
  
Table 2 Summary of complications. 
Parameter  N (%) or median [IQR] Effect: 
NG + prokinetics NI Size 95% CI % of NI  
> median NG 
Complications:      
Adverse event: occurrence 9 9 [7*1+1*2] 0.16 0, 0.38 - 
Adverse event: patients 9 8 0.04 0, 0.32 - 
Serious adverse event: 
occurrence 
8 [6*1+1*2] 6 0.14 0, 0.36 - 
Serious adverse event: patients 7 6 0.05 0, 0.33 - 
Ventilation free days 20 [13-25] 21 [16-25] 0.08 -5, 3 56% 
ICU free days 11 [0-19] 10 [0-16] 0.02 -4, 6 48% 
Death 4 (16%) 4 (16%) 0 0, 0.32 - 
 
Appendix A: Baseline characteristics of inclusions v exclusions. 
Parameter Inclusion Exclusion Effect size:  
 Median 
or % 
IQR Median or 
% 
IQR Size 95%CI *% of NI  
> median NG 
Age (y) 51.5  [40-60.5] 55  [37-71.5] 0.09 -0.04, 0.22 46 
APACHE II score 18  [12.3-24] 16  [11-23] 0.06 0.07, 0.19 56 
Outcomes:        
■ ICU free 11  [4-18.3] 17  [10-22.3] 0.23 0.10, 0.36 32 
■ Ventilation free days 16.5  [10-20.8] 21.5  [15-24] 0.27 0.14, 0.39 40 
■ Death 16% - 28% - 0.10 - - 
*For categorical variables the median is meaningless.  
Appendix B Enteral volume and kcal delivered and gastric loss. 
Parameter Day Inclusion Exclusion Effect: 
  Med. IQR Med. IQR Size 95% 
CI 
*% of NI 
> 
median 
NG 
Gastric 
Loss  
(mL) 
-2 370 0-837 560 200-760 0.04 0.25, 
0.31 
60% 
-1 850 350-
1115 
885 590-1090 0.07 0.21, 
0.36 
52% 
1 250 0-460 690 400-1055 0.43 0.15, 
0.66 
84% 
2 0 0-58 480 162-975 0.58 0.37, 
0.76 
92% 
3 0 0-0 455 246-898 0.71 0.51, 
0.87 
92% 
4 0 0-205 295 19-739 0.29 0.00, 
0.55 
76% 
5 0 0-181 69 0-482 0.27 0.04, 
0.55 
60% 
EN 
delivered  
(mL) 
-2 1104 608-
1476 
1190 734-1618 0.10 -495, 
231 
60% 
-1 1117 619-
1480 
964 785-1494 0.04 -335, 
420 
40% 
1 1124 744-
1471 
1497 1405-1593 0.37 -673,  -
67 
92% 
2 1650 1245-
1944 
1808 1384-1947 0.11 -493, 
179 
64% 
3 1726 1108-
1988 
1880 1658-2172 0.23 -691, 
72 
68% 
4 1492 893-
2080 
1945 1634-2382 0.37 -1022, 
-112 
92% 
5 1585 1261-
1946 
1917 1491-2392 0.31 -921,  -
52 
76% 
Kcal 
Delivered 
-2 1300 685-
1645 
1184 758-1478 0.01 -321, 
377 
56% 
-1 1338 363-
1680 
1002 657-1237 0.23 -69, 
654 
24% 
1 1249 783-
1594 
1510 1428-1611 0.18 -565,  -
11 
84% 
2 1718 1274-
1842 
1791 1396-2159 0.07 -424, 
89 
56% 
3 1883 988-
2206 
1750 1523-2030 0.11 -391, 
374 
44% 
4 1579 913-
2224 
1805 1589-2115  -770, 
310 
76% 
5 1729 1354-
2071 
1684 1535-2128  -602, 
290 
52% 
 
 
Appendix C Associations with %goal tolerated. 
 Estimate Std. Error t value Pr(>|t|) 
     
Intercept -165.422 282.002 -0.587 0.561 
Treatment group = NI 145.863 47.176 3.092 0.004 
Disease category = Neurosurgical (non-Trauma) 95.033 61.408 1.548 0.130 
Disease category = Surgery (general) -187.790 71.155 -2.639 0.012 
Disease category = Trauma -32.590 62.778 -0.519 0.607 
Age -1.437 1.593 -0.902 0.373 
Apache II score 4.359 3.858 1.130 0.266 
Conscious state = sedated -34.985 74.729 -0.468 0.642 
Conscious state = unconscious -9.960 96.216 -0.104 0.918 
Airway = endotracheal tube 159.070 178.253 0.892 0.378 
Airway = tracheostomy 4.732 58.305 0.081 0.936 
Height (cm) -0.907 1.273 -0.712 0.481 
Weight (kg) 0.784 0.763 1.027 0.311 
 
Reference categories: Disease category = Medical; Conscious state = awake; Airway = endotracheal 
tube. 
Bold indicate significant independent associations with lower and higher cumulative deficits, 
respectively. 
  
Appendix D Breakdown of adverse and serious adverse events and reactions and PN 
use. 
Class Complication NG + prokinetic drugs NI 
GI Diarrhoea 2 0 
 Gastric distension 0 1 
 Vomited 5 3 
Infection Minor 0 0 
Metabolic CRRT 0 2 
 Hypernatraemia: Diuretic-induced 0 1 
 Raised LFTs 0 1 
Mechanical Minor nose bleed 0 2 
Drug Ileus: Erythromycin stopped 1 0 
 Skin rash: Erythromycin stopped 1 0 
GI Ileus 1 3 
Infection Systemic: Candidiasis 1 0 
 Systemic: VAP 4 2 
Metabolic All 0 0 
Mechanical All 0 0 
Drug Tachycardia, ectopics, loss of output: Erythromycin 
stopped 
1 0 
PN Patients 2 2 
 Patient days 9 5 
 
 
